Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Lihua Qiu(Tianjin Medical University Cancer Institute and Hospital), Chuan Jin(Guangzhou Medical University), Huizheng Bao(Jilin Province Tumor Hospital), Hui Zhou(Hunan Cancer Hospital), Jianmin Yang(Canadian Food Inspection Agency), Tao Sun(Liaoning Cancer Hospital & Institute), Jianda Hu(Fujian Medical University), Xiuhua Sun(Dalian Medical University), Hang Su(307th Hospital of Chinese People’s Liberation Army), Ou Bai, Yongping Song(First Affiliated Hospital of Zhengzhou University), Yarong Li(Second Affiliated Hospital of Jilin University), Mingzhi Zhang(Soochow University), Dong Wang(Zhejiang Chinese Medical University), Li Liu(Air Force Medical University), Zhao Wang(Capital Medical University), Yu Yang(Fujian Provincial Cancer Hospital), Jifeng Feng(Zhejiang Cancer Hospital), Huaqing Wang(Tianjin People's Hospital), Gan Fu(Central South University), Yu Ding(Hubei Cancer Hospital), Xin Du(Changchun University of Science and Technology), Guoan Chen(Southern University of Science and Technology), Zhengming Jin(Soochow University), Jie Jin(Beijing Institute of Technology), Wenbin Qian(Second Affiliated Hospital of Zhejiang University)
Cited by 4
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k